Siltuximab, another monoclonal antibody targeting IL-6, had minimal effects in a phase I study [194, 195] and exhibited no benefits in a phase II clinical trial in patients with refractory/relapse MM [196]. Here, IL6 is linked to Miyoshi myopathy.